UCB SA (OTCMKTS:UCBJF) Short Interest Up 25.7% in January

UCB SA (OTCMKTS:UCBJF - Get Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 396,800 shares, a growth of 25.7% from the January 15th total of 315,600 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is presently 3,968.0 days.

UCB Price Performance

UCBJF stock traded down $1.00 during trading on Tuesday, reaching $190.00. The company's stock had a trading volume of 55 shares, compared to its average volume of 160. The company's fifty day moving average is $191.65 and its 200-day moving average is $182.20. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. UCB has a 1 year low of $110.35 and a 1 year high of $200.00.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.